Lapatinib-Veliparib Drug Combination As Treatment Option for Triple Negative Breast Cancer

 “If you hit triple-negative cancer cells with lapatinib, among other things, it breaks down the ability of the cell to repair its DNA,” Yang explains. “By utilizing the PARP inhibitor on top of that, the cancer cell continues to accumulate damage to its DNA, causing the cell to die. This potent combination causes an interaction that is lethal to triple-negative breast cancer cells.”

http://www.uab.edu/news/briefs/item/2841-uab-study-reveals-novel-treatment-option-for-triple-negative-breast-cancer (Click link for full story)